Beigene, Ltd. (NASDAQ:ONC - Get Free Report)'s stock price gapped up before the market opened on Thursday . The stock had previously closed at $250.92, but opened at $264.02. Beigene shares last traded at $264.23, with a volume of 155,764 shares changing hands.
Wall Street Analysts Forecast Growth
ONC has been the subject of several research analyst reports. Sanford C. Bernstein set a $259.00 target price on Beigene in a research report on Thursday, March 13th. Macquarie boosted their price objective on shares of Beigene from $259.00 to $313.00 and gave the company an "outperform" rating in a report on Friday, February 28th. Bank of America upgraded shares of Beigene from a "neutral" rating to a "buy" rating and raised their target price for the stock from $207.00 to $320.00 in a report on Monday, March 3rd. Guggenheim reissued a "buy" rating on shares of Beigene in a report on Friday, February 28th. Finally, JMP Securities set a $348.00 price target on Beigene in a research note on Friday, February 28th.
Read Our Latest Analysis on Beigene
Beigene Trading Down 0.5 %
The stock has a market cap of $26.25 billion, a PE ratio of -32.30, a P/E/G ratio of 7.73 and a beta of 0.65. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.72 and a current ratio of 1.93.
Beigene (NASDAQ:ONC - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.55). Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The business had revenue of $1.13 billion for the quarter, compared to the consensus estimate of $1.09 billion. On average, equities analysts predict that Beigene, Ltd. will post -5.82 EPS for the current fiscal year.
Insider Activity at Beigene
In related news, insider Xiaodong Wang sold 8,146 shares of Beigene stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $254.58, for a total transaction of $2,073,808.68. Following the sale, the insider now owns 5,240,882 shares of the company's stock, valued at approximately $1,334,223,739.56. This trade represents a 0.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO John Oyler sold 101,000 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $244.30, for a total value of $24,674,300.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,052,367 shares of company stock worth $270,454,249. 7.43% of the stock is owned by company insiders.
Beigene Company Profile
(
Get Free Report)
BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
Featured Stories
Before you consider Beigene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beigene wasn't on the list.
While Beigene currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
